Indian J Med Microbiol Close
 

Figure 2: Psoriasis Area and Severity Index 90 at week 12 across three Phase III studiesa with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *P < 0.001, **P < 0.0001, aComparator: Placebo in ERASURE, Etanercept in FIXTURE and ustekinumab in CLEAR. ERASURE: Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis; FIXTURE: Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis, CLEAR: Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab

Figure 2: Psoriasis Area and Severity Index 90 at week 12 across three Phase III studies<sup>a</sup> with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *<i>P</i> < 0.001, **<i>P</i> < 0.0001, <sup>a</sup>Comparator: Placebo in ERASURE, Etanercept in FIXTURE and ustekinumab in CLEAR. ERASURE: Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis; FIXTURE: Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis, CLEAR: Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab